ArticleJAMA network open2023
Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement.
Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation Between Online Case-based Training of Pathologists in Dermoscopic Images and Diagnostic Accuracy in Histopathological Interpretation of Skin Lesions Suspicious of Melanoma
Diagnostic Agreement Among Expert Dermatopathologists on Skin Lesions Clinically Suspicious of Melanoma
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Natural language processing in dermatology: A systematic literature review and state of the art.Journal of the European Academy of Dermatology and Venereology : JEADV · 2024Pooled it
- Management of dysplastic nevus by Italian dermatologists: a survey of the Italian Association of Hospital Dermatologists (ADOI).Dermatology reports · 2026Article
- Article
- Surgical Management of Cutaneous Neoplasms: Biopsy Strategies, Margin Assessment, and Special Considerations.Dermatopathology (Basel, Switzerland) · 2026Review
- [Melanocytic nevi in focus : Clinical interpretation, histopathological criteria, and practice-oriented management].Dermatologie (Heidelberg, Germany) · 2026Article
- Retrospective multicenter study on severely dysplastic melanocytic nevi: evaluating the need for re-excision and the risk of recurrence or progression.Dermatology reports · 2026Article
- WHO classification of skin tumours: key updates in the fifth edition.Histopathology · 2026Review
- In vivo molecular skin fluorescence imaging for noninvasive assessment of atypical nevi and melanoma: A validation trial.JAAD international · 2026Article
- Grading Melanocytic Dysplasia: Updated Histopathologic Criteria.Journal of cutaneous pathology · 2026Review
- The Role of Stromal Tumor Environment in Advancing Skin Cancer Diagnosis and Treatment.International journal of dermatology · 2025Review
- Towards a transcriptomic biomarker for the classification of melanocytic neoplasms.PLoS genetics · 2025Article
- Local Recurrence and Survival in Patients With Melanoma In Situ.JAMA dermatology · 2025Article
- Improving diagnostic accuracy in atypical melanocytic tumors using p16 immunohistochemistry and 9p21 fluorescence in situ hybridization: analysis of 206 second opinion cases.Scientific reports · 2025Article
- Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Robust ROI Detection in Whole Slide Images Guided by Pathologists' Viewing Patterns.Journal of imaging informatics in medicine · 2025Article
- Dysplastic Nevi and Superficial Borderline Atypical Melanocytic Lesions: Description of an Algorithmic Clinico-Pathological Classification.Dermatopathology (Basel, Switzerland) · 2025Review
- Article
- Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma-What's in a Name?JAMA dermatology · 2024Article
- The 2023 WHO updates on skin tumors: advances since the 2018 edition.Pathologica · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
Importance: A standardized pathology classification system for melanocytic lesions is needed to aid both pathologists and clinicians in cataloging currently existing diverse terminologies and in the diagnosis and treatment of patients. The Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) has been developed for this purpose. Objective: To revise the MPATH-Dx version 1.0 classification tool, using feedback from dermatopathologists participating in the National Institutes of Health-funded Reducing Errors in Melanocytic Interpretations (REMI) Study and from members of the International Melanoma Pathology Study Group (IMPSG). Evidence Review: Practicing dermatopathologists recruited from 40 US states participated in the 2-year REMI study and provided feedback on the MPATH-Dx version 1.0 tool. Independently, member dermatopathologists participating in an IMPSG workshop dedicated to the MPATH-Dx schema provided additional input for refining the MPATH-Dx tool. A reference panel of 3 dermatopathologists, the original authors of the MPATH-Dx version 1.0 tool, integrated all feedback into an updated and refined MPATH-Dx version 2.0. Findings: The new MPATH-Dx version 2.0 schema simplifies the original 5-class hierarchy into 4 classes to improve diagnostic concordance and to provide more explicit guidance in the treatment of patients. This new version also has clearly defined histopathological criteria for classification of classes I and II lesions; has specific provisions for the most frequently encountered low-cumulative sun damage pathway of melanoma progression, as well as other, less common World Health Organization pathways to melanoma; provides guidance for classifying intermediate class II tumors vs melanoma; and recognizes a subset of pT1a melanomas with very low risk and possible eventual reclassification as neoplasms lacking criteria for melanoma. Conclusions and Relevance: The implementation of the newly revised MPATH-Dx version 2.0 schema into clinical practice is anticipated to provide a robust tool and adjunct for standardized diagnostic reporting of melanocytic lesions and management of patients to the benefit of both health care practitioners and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.